Autoimmune targeting of vasoactive neuropeptides (VIP, PACAP) at the blood-brain/spinal barrier is postulated to contribute to multiple neuropsychiatric conditions including demyelinating and neurodegenerative diseases.
Key findingAutoimmune targeting of vasoactive neuropeptides (VIP, PACAP) at the blood-brain/spinal barrier is postulated to contribute to multiple neuropsychiatr
What the researchers found
Autoimmune targeting of vasoactive neuropeptides (VIP, PACAP) at the blood-brain/spinal barrier is postulated to contribute to multiple neuropsychiatric conditions including demyelinating and neurodegenerative diseases.
Why it matters
Relevant for peptide research.
How the study worked
research study.
What this study cannot tell us
See abstract.
How to read the evidence
emerging evidence.
When this study was published
Published in 2009.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
Common questions
What was studied?
What was found?
Read the original research
Postulated vasoactive neuropeptide immunopathology affecting the blood-brain/blood-spinal barrier in certain neuropsychiatric fatigue-related conditions: A role for phosphodiesterase inhibitors in treatment?
Neuropsychiatric disease and treatment, 5, 81-9
Citation
Staines, Donald R; Brenu, Ekua W; Marshall-Gradisnik, Sonya. (2009). Postulated vasoactive neuropeptide immunopathology affecting the blood-brain/blood-spinal barrier in certain neuropsychiatric fatigue-related conditions: A role for phosphodiesterase inhibitors in treatment?. Neuropsychiatric disease and treatment, 5, 81-9.